Who is the CEO of CG Invites?

According to the DART company overview, CG Invites' representative director is 이호영 (name as registered in Korean). The company was founded on 2000-07-07.

Where is CG Invites listed?

CG Invites trades on the Korea Exchange KOSDAQ market under the ticker 083790. Its fiscal year ends in December.

Does CG Invites pay a dividend?

CG Invites did not pay a cash dividend for fiscal 2025, according to its annual report.

Does CG Invites have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: 4 quarters of losses (operating loss in each of the last four quarters); Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); M&A / stake deal (merger, spin-off or acquisition/sale of shares in another company (90 days)). These are factual flags, not investment advice.

Which companies are in the same industry as CG Invites?

Under the Korean Standard Industrial Classification recorded on DART, CG Invites is grouped with 53 other listed companies in medical & pharmaceutical r&d. The most covered in Korean news over the past 30 days are Alteogen, D&D Pharmatech and LigaChem Biosciences.

CG Invites KRX:083790KOSDAQ

CG인바이츠 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days1

DART filings, 7 days0

Articles tracked11since Sep 11

In Q2 2026, CG Invites reported revenue of ₩4.6bn, down 25.3% year on year, and an operating loss of ₩5.9bn. CG Invites (CG인바이츠) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Nov 12 with 1 article.

Filing signals M&A / stake deal 4 quarters of losses Share pledge Screener

CG Invites quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩4.6bn	-25.3%	−₩5.9bn margin −127.3%	−₩7.5bn
Q1 2026	₩4.3bn	+39.2%	−₩6.1bn margin −142.3%	−₩5.8bn
Q4 2025 derived	₩12.0bn	+338.9%	−₩3.8bn margin −31.6%	₩17.3bn
Q3 2025	₩6.1bn	+276.2%	−₩6.9bn margin −112.4%	−₩12.7bn
Q2 2025	₩6.2bn	+183.4%	−₩7.9bn margin −127.8%	−₩11.7bn
Q1 2025	₩3.1bn	+334.5%	−₩5.2bn margin −168.1%	−₩5.4bn
Q4 2024 derived	₩2.7bn	+159.0%	−₩21.3bn	−₩22.7bn
Q3 2024	₩1.6bn	+165.7%	−₩3.9bn margin −239.6%	−₩7.4bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

CG Invites top stories 2 weeks, by number of outlets

1
CG Invites presents mRNA cancer vaccine efficiency improvement research at AACR-KCA
1 outlets · 1 articlesFirst report Nov 12 14:59 머니투데이

Latest CG Invites news Korean headlines

Nov 1214:59

CG Invites presents mRNA cancer vaccine efficiency improvement research at AACR-KCA
머니투데이
Nov 121:09

CG Invites largest shareholder increases collateral contract by 480,000 shares
비건뉴스
Oct 1914:24

CG Invites subsidiary InvitesVentures on M&A block
뉴스톱
Sep 2815:06

MajorCG Invites exports InvitesLoop technology to mainland China, secures JV stake and royalties
PRESS9Licensing deal
Sep 1816:19

CG Invites invests 9.4 billion won in Hong Kong digital health joint venture, secures 43.7% stake
더바이오
Sep 1816:05

CG Invites acquires 9.4 billion won worth of Vista shares, secures 43.7% stake
연합뉴스경제
Sep 1714:49
CG Invites accelerates China push with InvitesLoop, establishes Hong Kong joint venture
블로터
2 more on this story · 2 outlets
- CG Invites establishes Hong Kong joint venture with Chinese medical institution Vista, accelerates China business더바이오 · Sep 17 15:28
- CG Invites establishes Hong Kong joint venture with Vista, targets digital healthcare딜사이트 · Sep 17 16:39
Sep 1714:25
CG Invites establishes Hong Kong JV with VISTA, enters China's digital healthcare market
PRESS9
1 more on this story · 1 outlets
- CG Invites enters China's digital healthcare market, establishes Hong Kong JV파이낸셜뉴스 · Sep 17 14:32

Articles per day 2 weeks

112

Company profile

CEO: 이호영
Industry: Medical & pharmaceutical R&D
Founded: 2000-07-07
Fiscal year-end: December
Head office: 서울특별시 강서구
Website: cginvites.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

뉴레이크인바이츠투자33.87%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Medical & pharmaceutical R&D

All in industry

Company	Latest quarter op. profit	Articles 30d
Alteogen	–	255
D&D Pharmatech	−₩13.6bn	72
LigaChem Biosciences	−₩50.4bn	69
Curocell	−₩7.7bn	51
SillaJen	–	44
OliX Pharmaceuticals	–	42
Qurient	−₩7.0bn	41
GI Innovation	–	41

Compare CG Invites side by side with these companies

CG Invites DART filings

Oct 2617:11

Report on large shareholdings in securities (general)
Ownership reports
Sep 3016:11

Results of extraordinary shareholders' meeting
Other
Sep 2819:12

[Corrected filing] Decision on acquisition of stocks and investment securities of other companies
Contracts & investment
Sep 1816:04

Decision on acquisition of shares and investment securities of other companies
Contracts & investment
Sep 1518:00

Convocation of shareholders' meeting (extraordinary general meeting)
Other
Sep 1517:57

Notice of shareholders' meeting
Other
Sep 1013:37

Correction: Single sales/supply contract execution
Contracts & investment

Mentioned alongside 2 weeks

No co-mentioned companies yet.

CG Invites FAQ

Who is the CEO of CG Invites?: According to the DART company overview, CG Invites' representative director is 이호영 (name as registered in Korean). The company was founded on 2000-07-07.
Where is CG Invites listed?: CG Invites trades on the Korea Exchange KOSDAQ market under the ticker 083790. Its fiscal year ends in December.
What were CG Invites' latest quarterly results?: In Q2 2026, CG Invites reported revenue of ₩4.6bn, down 25.3% year on year, and an operating loss of ₩5.9bn. Figures come from reports filed on DART.
Does CG Invites pay a dividend?: CG Invites did not pay a cash dividend for fiscal 2025, according to its annual report.
Does CG Invites have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: 4 quarters of losses (operating loss in each of the last four quarters); Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); M&A / stake deal (merger, spin-off or acquisition/sale of shares in another company (90 days)). These are factual flags, not investment advice.
Which companies are in the same industry as CG Invites?: Under the Korean Standard Industrial Classification recorded on DART, CG Invites is grouped with 53 other listed companies in medical & pharmaceutical r&d. The most covered in Korean news over the past 30 days are Alteogen, D&D Pharmatech and LigaChem Biosciences.